GlassScriptPhysician profile
Rachel Chua
NPI 1871573030
$2,235.54
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $168 · 2021: $486 · 2022: $662 · 2023: $237 · 2024: $15.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $252.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $674.50 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $228.06 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $203.03 | 2019-2023 | Trintellix |
| Avion Pharmaceuticals | $132.94 | 2019-2022 | |
| Evofem Biosciences, INC. | $115.58 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $105.69 | 2021-2023 | Contrave, Onzetra Xsail |
| Mayne Pharma Commercial LLC | $82.55 | 2021-2023 | |
| Astellas Pharma US INC | $79.19 | 2022-2024 | Veozah |
| Amag Pharmaceuticals, INC. | $69.78 | 2019-2020 | |
| Duchesnay USA Incorporated | $65.42 | 2019 | |
| Vivus LLC | $51.33 | 2019 | |
| Myovant Sciences INC. | $45.52 | 2022 | |
| Therapeuticsmd, INC. | $44.40 | 2019-2022 | |
| Novo Nordisk INC | $42.10 | 2019-2020 | |
| Hologic Sales and Service, LLC | $36.05 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $32.12 | 2019 | |
| Amgen INC. | $30.78 | 2019 | |
| Exeltis, USA INC. | $30.29 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.86 | 2022 | |
| Agile Therapeutics, INC. | $24.55 | 2023 | Twirla |
| Coloplast Corp | $24.06 | 2021 | |
| Axsome Therapeutics, INC. | $21.60 | 2023 | Auvelity |
| Organon LLC | $16.67 | 2022 | |
| Merck Sharp & Dohme LLC | $15.76 | 2021 | |
| Scynexis, INC. | $13.36 | 2022 | |
| Millicent US INC | $12.45 | 2020 | |
| Vertical Pharmaceuticals, LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Chua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.